Using breath testing to track response to treatment in pleural mesothelioma
Tests an E-Nose breath test to track treatment response in adults with pleural mesothelioma.
Plain-language title generated from the registry record
Registry title: Using E-Nose Technology to Measure Response to Treatment in People With Malignant Pleural Mesothelioma
Key facts
- Where
- Basking Ridge, Commack, Harrison, Middletown, Montvale, New York, and Uniondale, United StatesSee the 7 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 30 and 85 years old?
Source: NCT06037941, who can take part
Where in United States
- Memorial Sloan Kettering Basking Ridge (Consent Only)Basking Ridge, United StatesTaking people
- Memorial Sloan Kettering Cancer Center @ Suffolk-Commack (Consent only)Commack, United StatesTaking people
- Memorial Sloan Kettering Westchester (Consent only)Harrison, United StatesTaking people
- Memorial Sloan Kettering Monmouth (Consent Only)Middletown, United StatesTaking people
- Memorial Sloan Kettering Bergen (Consent Only)Montvale, United StatesTaking people
- Memorial Sloan Kettering Cancer Center (All Protocol Activities)New York, United StatesTaking people
- Memorial Sloan Kettering Nassau (Consent Only)Uniondale, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Memorial Sloan Kettering Cancer Center
- Trial code
- NCT06037941
- Record updated
- 24 September 2026
- Original description
The researchers are doing this study to test the ability of a new technology called breathprinting, or electronic nose (E-Nose), to measure how people respond to standard treatment for malignant pleural mesothelioma (MPM). The researchers will study how E-Nose breathprints change over time as people receive standard treatment for MPM. They will also look at how changes in people's E-Nose breathprints compare to changes in their standard imaging scans and in biomarkers of MPM in their blood.Read full original descriptionShow less
Breathprinting (E-Nose) Technology to Measure Response to Treatment of Malignant Pleural Mesothelioma (MPM) Through MPM-Specific Volatile Organic Compounds Detected in Exhalates
The researchers are doing this study to test the ability of a new technology called breathprinting, or electronic nose (E-Nose), to measure how people respond to standard treatment for malignant pleural mesothelioma (MPM). The researchers will study how E-Nose breathprints change over time as people receive standard treatment for MPM. They will also look at how changes in people's E-Nose breathprints compare to changes in their standard imaging scans and in biomarkers of MPM in their blood.
Inclusion: Aged 30-85 years; No history of thoracic cancer or extrathoracic cancer potentially involving pleural metastases (i.e., breast, gastric, colon, or pancreas cancer); Recent diagnosis of MPM; Documented, signed, and dated informed consent, obtained before any procedures, for the proposed research study, and signed standard surgical consent for surgical resection.
Exclusion: History of thoracic or extrathoracic cancer that puts the subject at risk for pleural or pulmonary metastases; Aged <30 or >85 years at the first outpatient visit.